[Review of plasma anti-aggregants and their indications in primary care. Eight years later].
作者信息
Blasco Valle M, Lucía Cuesta J F
机构信息
Centro de Salud Delicias Sur. Zaragoza. España.
出版信息
Aten Primaria. 2003 Mar 15;31(4):252-63. doi: 10.1016/s0212-6567(03)79168-9.
Abstract
摘要
相似文献
1
[Review of plasma anti-aggregants and their indications in primary care. Eight years later].
Aten Primaria. 2003 Mar 15;31(4):252-63. doi: 10.1016/s0212-6567(03)79168-9.
2
[Platelet anti-aggregants, from the concept to clinical results].
Rev Prat. 1988 Dec 8;38(30):2268-71.
3
[Platelet antiaggregants: a review of their indications in primary care].
Aten Primaria. 1993 Feb 28;11(3):142-6, 148-50.
4
[The treatment of cerebrovascular disorders with anticoagulants and platelet aggregation inhibitors].
Rev Neurol. 1999;29(12):1285-90.
5
[Oral anticoagulants and platelet anti-aggregants in the prevention of metastases: state of the art and perspectives of a combined therapy].
Recenti Prog Med. 1989 Jan;80(1):28-32.
6
[Attempts to prevent intrauterine growth retardation using platelet anti-aggregants].
Rev Fr Gynecol Obstet. 1990 Mar;85(3):141-3.
7
[Use of ticlopidine in primary care].
Aten Primaria. 1996 Mar 31;17(5):361-2.
8
Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide.
Am J Hematol. 2005 Sep;80(1):81-3. doi: 10.1002/ajh.20399.
9
Antiplatelet therapy in women with acute coronary syndrome.
J Fam Pract. 2014 Feb;63(2 Suppl):S3-8.
10
Cardiovascular risk management in diabetes in primary care.
J Pak Med Assoc. 2015 Aug;65(8):907-8.
本文引用的文献
1
SYSTEMIC EMBOLISM AND ANTICOAGULANT PROPHYLAXIS IN RHEUMATIC HEART DISEASE.
Br Med J. 1964 May 9;1(5392):1209-12. doi: 10.1136/bmj.1.5392.1209.
2
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
BMJ. 2002 Jan 12;324(7329):71-86. doi: 10.1136/bmj.324.7329.71.
3
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
N Engl J Med. 2001 Aug 16;345(7):494-502. doi: 10.1056/NEJMoa010746.
4
Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project.
Lancet. 2001 Jan 13;357(9250):89-95. doi: 10.1016/s0140-6736(00)03539-x.
5
[The effect of triflusal on human platelet aggregation and secretion: the role of nitric oxide].
Rev Esp Cardiol. 2000 Feb;53(2):205-11. doi: 10.1016/s0300-8932(00)75085-8.
6
Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.
Eur Heart J. 2000 Mar;21(6):457-65. doi: 10.1053/euhj.1999.1874.
7
Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes.
Lancet. 2000 Jan 29;355(9201):337-45.
8
Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists.
Lancet. 2000 Jan 29;355(9201):330-1. doi: 10.1016/S0140-6736(99)00464-X.
9
A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.
Arch Intern Med. 1999 Sep 27;159(17):2041-50. doi: 10.1001/archinte.159.17.2041.
10
The effect of withdrawal of drugs treating intermittent claudication.
Am J Surg. 1999 Aug;178(2):141-6. doi: 10.1016/s0002-9610(99)00147-6.
Zotero 插件